基于Survivin、Livin凋亡抑制蛋白探讨化痰消瘀方逆转胃癌癌前病变的作用机制

Traditional Chinese medicine for precancerous lesions of gastric cancer: A review

Gastric cancer (GC) is the fifth most common type of cancer and the third leading cause of death due to cancer worldwide. The gastric mucosa often undergoes many years of precancerous lesions of gastric cancer (PLGC) stages before progressing to gastric malignancy. Unfortunately, there are no effective Western drugs for patients with PLGC. In recent years, traditional Chinese medicine (TCM) has been proven effective in treating PLGC. Classical TCM formulas and chemical components isolated from some Chinese herbal medicines have been administered to treat PLGC, and the main advantage is their comprehensive intervention with multiple approaches and multiple targets. In this review, we focus on recent studies using TCM treatment for PLGC, including clinical observations and experimental research, with a focus on targets and mechanisms of drugs. This review provides some ideas and a theoretical basis for applying TCM to treat PLGC and prevent GC.

Effect of Huatan Xiaoyu decoction on serum tumor markers in patients with precancerous lesions of gastric cancer

AIM: To observe the clinical efficacy of Huatan Xiaoyu decoction (HXD) in the treatment of precancerous lesions of gastric cancer (PLGCs), and its effect on tumor markers in serum.

METHODS: Two hundred patients with PLGCs were orally given HXD twice per day. The therapeutic course for all patients was six months. The therapeutic efficacy was assessed, and pathological changes were evaluated after electronic gastroscopy and biopsy. Serum levels of tumor markers were determined using electrochemical luminescence immunoassay.

RESULTS: Total effective rate was 88%. Symptom improvement, endoscopic and pathologic changes after treatment were significantly better than those before treatment (P < 0.05). The contents of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA72-4, and CA125 in serum were significantly lower after treatment than before treatment (P < 0.05).

CONCLUSION: HXD could prevent the progression of PLGCs by lowering serum CEA, CA19-9, CA72-4 and CA125 levels. Our findings provide an objective basis for the treatment of PLGCs to reduce the risk of cancer.